Apixaban for the prevention of venous thromboembolism in people ...

[12] Appendix 4: Searching for adverse effects [Internet]. In: Centre for Reviews and Dissemination.
Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of
York, 2009 [cited 27.04.11]. 253-254p. Available from: http://www.york.ac.uk/inst/crd/SysRev/-
!SSL!/WebHelp/SysRev3.htm
[13] Kleijnen Systematic Reviews (KSR) Ltd. Apixaban for prevention VTE after elective THR and
TKR – request for clarification from the manufacturer. York: KSR Ltd., 2011: 3p.
[14] Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for
thromboprophylaxis after knee replacement. N Engl J Med 2009;361(6):594-604.
[15] Bristol-Myers Squibb Pharmaceuticals Ltd., Pfizer Ltd. Clinical study report for study CV185034
(ADVANCE 1). A phase 3 randomised, double-blind, active-controlled (enoxaparin), parallelgroup,
multi-centre study to evaluate the safety and efficacy of oral apixaban in subjects
undergoing elective total knee replacement surgery. [Data on file], 2009
[16] Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for
thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lancet 2010;375(9717):807-15.
[17] Bristol-Myers Squibb Pharmaceuticals Ltd., Pfizer Ltd. Clinical study report for study CV185047
(ADVANCE 2). A phase 3, randomised, double-blind, active-controlled (enoxaparin 40 mg QD),
parallel group, multi-centre study to evaluate the safety and efficacy of apixaban in subjects
undergoing elective total knee replacement surgery. [Data on file], 2009
[18] Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin
for thromboprophylaxis after hip replacement. N Engl J Med 2010;363(26):2487-98.
[19] Bristol-Myers Squibb Pharmaceuticals Ltd., Pfizer Ltd. Clinical Study Report for Study
CV185035. A phase 3, randomized, double-blind, active-controlled, parallel-group, multicenter
study to evaluate the safety and efficacy of apixaban in subjects undergoing elective total hip
replacement surgery (The Advance-3 Study Apixaban Dosed Orally Versus AntiCoagulation with
Injectable Enoxaparin to prevent venous thromboembolism) [Data on file], 2009
[20] Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of
apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total
knee replacement. J Thromb Haemost 2007;5(12):2368-75.
[21] Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran
etexilate versus enoxaparin for prevention of venous thromboembolism after total hip
replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370(9591):949-56.
[22] Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran
versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE
II*): a randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105(4):721-9.
72
Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.